Literature DB >> 15817511

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.

Jaume Sastre-Garriga1, Gordon T Ingle, Declan T Chard, Mara Cercignani, Lluís Ramió-Torrentà, David H Miller, Alan J Thompson.   

Abstract

We have recently reported brain atrophy in the early stages of primary progressive multiple sclerosis (PPMS), affecting both grey and white matter (GM and WM). However, to date no clinical or radiological predictors of GM and WM atrophy have been identified. The aim was to investigate short-term changes in GM and WM volumes and to assess the predictive value of demographic, clinical and radiological variables in order to gain a better understanding of the pathological substrate underlying these changes. Thirty-one subjects with PPMS within 5 years of symptom onset were studied at baseline and after 1 year. At baseline, patients underwent neurological examination and were scored on the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite. They had 3D inversion-prepared fast spoiled gradient recalled (FSPGR), dual-echo and triple-dose post-contrast T1-weighted spin echo MRI scans. Proton density and enhancing lesion loads were determined. The 3DFSPGR sequence was repeated after 1 year and brain volume changes were calculated using two techniques, SPM99 (statistical parametric mapping) and SIENA (structural image evaluation, using normalization, of atrophy). Stepwise linear regression models were applied to baseline variables to identify independent predictors of atrophy development. Using SPM99, a decrease in brain parenchymal fraction (-1.03%; P < 0.001) and GM fraction (-1.49%; P < 0.001) was observed. The number of enhancing lesions independently predicted decrease in brain parenchymal fraction (P = 0.019) and decrease in WM fraction (P = 0.002). No independent predictors of GM fraction decrease were found. A mean brain volume change of -0.63% (range -4.27% to +1.18%; P = 0.002) was observed using SIENA, which was independently predicted by EDSS (P = 0.004). Global and GM atrophy can be detected over a 1-year period in early PPMS. The former may be predicted by the degree of inflammation, while the latter seems to be independent of it. SIENA and SPM-based methods appear to provide complementary information.

Entities:  

Mesh:

Year:  2005        PMID: 15817511     DOI: 10.1093/brain/awh498

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  39 in total

1.  MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis.

Authors:  P Tortorella; M A Rocca; D M Mezzapesa; A Ghezzi; L Lamantia; G Comi; M Filippi
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 2.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

Review 3.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 4.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

5.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

6.  Putaminal alteration in multiple sclerosis patients with spinal cord lesions.

Authors:  Hilga Zimmermann; Hans O Rolfsnes; Swantje Montag; Janine Wilting; Amgad Droby; Eva Reuter; Joachim Gawehn; Frauke Zipp; Adriane Gröger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

7.  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Authors:  J Furby; T Hayton; D Altmann; R Brenner; J Chataway; K J Smith; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2010-05-01       Impact factor: 4.849

8.  Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases.

Authors:  Sungpil Han; Yen Chih Lin; Tianxia Wu; Alan D Salgado; Ina Mexhitaj; Simone C Wuest; Elena Romm; Joan Ohayon; Raphaela Goldbach-Mansky; Adeline Vanderver; Adriana Marques; Camilo Toro; Peter Williamson; Irene Cortese; Bibiana Bielekova
Journal:  J Immunol       Date:  2014-02-07       Impact factor: 5.422

Review 9.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

Review 10.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.